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ABSTRACT: The Sondheimer dialkyne reagent has previously been employed in strain-promoted double-click cycloadditions with
bis-azide peptides to generate stapled peptide inhibitors of protein−protein interactions. The substituted variants of the Sondheimer
dialkyne can be used to generate functionalized stapled peptide inhibitors with improved biological properties; however, this remains
a relatively underdeveloped ﬁeld. Herein, we report the synthesis of new substituted variants of Sondheimer dialkyne and their
application in the stapling of p53-based diazido peptides to generate potent stapled peptide-based inhibitors of the oncogenic p53-
MDM2 interaction. The functionalized stapled peptide formed from a meta-ﬂuoro-substituted Sondheimer dialkyne was found to be
the most potent inhibitor. Furthermore, through experimental studies and density functional theory calculations, we investigated the
impact of the substituent on the strain-promoted double-click reactivity of Sondheimer dialkyne.
■ INTRODUCTION
Peptide stapling oﬀers a strategy to generate potent inhibitors of
protein−protein interactions (PPIs) by constraining short linear
peptides into their native alpha-helical conformation by forming
a covalent link between two of its amino acid side chains.1−6
Recently, a double strain-promoted peptide stapling approach
was developed by our group, utilizing a double strained
Sondheimer dialkyne reagent 1 (Figure 1a).7 Sondheimer
dialkyne 1 contains two strained alkynemoieties which allow the
linking of the two azide containing side chains on the linear
peptide in a metal-free environment via a double strain-
promoted click chemistry.8−10 This double strain-promoted
stapling approach has been successfully applied to the
development of stapled peptide inhibitors of the oncogenic
p53-MDM2 PPI, a validated target for anticancer therapeutics.7
The p53 protein is a tumor-suppressing transcription factor that
binds to an E3 ubiquitin ligase proteinMDM2which inhibits the
transcriptional activity of p53 and is overexpressed in some
cancers.11−13
One major general limitation of the double strain-promoted
stapling approach is the lack of functional groups on Sondheimer
dialkyne 1 and thus the resulting stapled peptides. It was
envisaged that the use of substituted Sondheimer dialkynes in
the stapling process would allow for the facile introduction of
diverse additional functionalities into stapled peptides, which
could impart novel physical properties and modify biological
activities. To explore this concept, we targeted the design and
synthesis of stapled peptide inhibitors of the p53-MDM2 PPI
which incorporated substituents on their aromatic ring systems
(Figure 1b).
Herein, we describe the synthesis of substituted variants of the
Sondheimer dialkyne and their application in the double strain-
promoted stapling of a p53 diazo peptide 2 to generate
previously unreported functionalized stapled peptide inhibitors
of the p53-MDM2 PPI. Substitution was shown to impact
signiﬁcantly upon the biological proﬁle of the stapled peptides,
with the pattern of substitution also being of great importance in
this regard. In this work, through both experimental and
computational studies, we also show how the presence of a
substituent on Sondheimer dialkyne inﬂuences its azide
reactivity in double strain-promoted click chemistry.
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Figure 1. (a) Previous work: use of Sondheimer dialkyne in double strain-promoted stapling of diazidopeptide to generate stapled peptide inhibitors of
PPIs. (b) This work: synthesis of functionalized stapled peptides for p53-MDM2 inhibition by application of substituted Sondheimer dialkynes in
double strain-promoted stapling of a p53-based diazido peptide.
Scheme 1. (a) Synthesis of Benzyl Sulfone-Substituted Aldehyde Substrates; (b) Synthesis of Substituted Sondheimer Dialkynes
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■ RESULTS AND DISCUSSION
Substituted Sondheimer Dialkyne Synthesis. Four
diﬀerent substituted variants of the Sondheimer dialkyne
bearing methoxy and ﬂuoro substituents at the meta and
ortho-positions relative to the alkyne moiety were targeted (11,
12, 13, and 14, Scheme 1a). Orita et al. had previously reported
the synthesis of the Sondheimer dialkyne from ortho-
(phenylsulfonylmethyl)benzaldehyde via a dimerization then
double-elimination sequence.14,15 It was envisaged that this
approach could be modiﬁed to allow access to the target
substituted Sondheimer dialkynes 11−14 from the correspond-
ing substituted benzyl sulfone aldehyde substrates 3, 4, 5, and 6
(Scheme 1a).
Substituted benzyl sulfone aldehyde substrates 3, 4, and 5
were readily accessed from commercially available starting
materials 15, 18, and 19 (Scheme 1b). Wohl−Ziegler
bromination ofmeta-ﬂuoro-substituted ester 15 and subsequent
treatment with benzenesulﬁnic acid aﬀorded sulfone ester 16.
DIBAL-H reduction of 16 followed by Dess−Martin oxidation
gave the desired meta-ﬂuoro-substituted aldehyde 3. The ortho-
ﬂuoro and meta-methoxy substituted sulfones 4 and 5 were
synthesized by treating arenes 18 and 19 to Wohl−Ziegler
bromination, followed by nucleophilic substitution with
benzenesulﬁnic acid sodium salt. Reduction of the resulting
sulfone nitriles 20 and 21 gave the desired aldehydes 4 and 5.
Sulfone 6 bearing a 3,4-dimethoxyphenylsulfonyl group was
synthesized by following the reported procedure.15
The sulfones 3−6 were subjected to Wittig−Horner
conditions in the presence of LiHMDS and diethyl chlor-
ophosphate to form the cyclized intermediates 7−10 (Scheme
1a).14 Subsequent treatment with LDA led to the elimination of
the phenylsulfonyl groups to aﬀord the desired substituted
dialkynes 11−14 in low-to-moderate yields. This method was
unsuccessful in the preparation of heteroaromatic (pyridine and
furan) based variants of Sondheimer dialkyne (see Supporting
Information 1.1).
Strain-Promoted Double-Click Peptide Stapling. The
substituted dialkynes 11−14 were then applied to the double
strain-promoted stapling of the p53-based diazido peptide PDI-
E 2 (Ac-LTFXEYWAQLXS-NH2, X = Orn(N3))16,17 in an
eﬀort to generate functionalized stapled peptide inhibitors of the
p53-MDM2 PPI. Peptide 2 was chosen for stapling as previous
work within our group has shown that the stapled peptide
generated from PDI-E peptide and Sondheimer dialkyne 1 is a
potent inhibitor of the p53-MDM2 interaction.7 Double strain-
promoted stapling of peptide 1 with substituted dialkynes 11−
14 proceeded successfully to deliver the corresponding
functionalized stapled peptides 22−25 in 22−39% yield
(Scheme 2).The functionalized stapled peptides are drawn as
a single isomer for simplicity. These functionalized stapled
peptides were then tested for their in vitro binding aﬃnity with
MDM2 in a competitive ﬂuorescence polarization (FP)2,18
assay. The meta-ﬂuoro derivative 22 (17.3 ± 7.7 nM) and meta-
methoxy derivative 24 (8.5 ± 1.9 nM)-functionalized stapled
peptides were found to be particularly potent binders of MDM2
(Table 1).
Next, the p53-MDM2 inhibitory activities of the function-
alized stapled peptides 22−25 in a p53 reporter cell-based assay
were evaluated.18 p53 reporter cells taken in a 96-well format
were treated with puriﬁed stapled peptides 22−25 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Figure 2a). The meta-
ﬂuoro-functionalized peptide 22 was found to be the most
potent inhibitor. Moreover, 23 and 24were also found to exhibit
slight inhibitory activity. p53 activation values are reported as
fold activation over the activation value obtained when cells
were treated with 1% dimethyl sulfoxide (DMSO). This
provides an indirect comparative measure of the cellular p53
levels, where higher values are indicative of increased cellular
activity. We also performed an in situ stapling assay where p53
reporter cells taken in a 96-well format were treated with linear
diazido peptide 2 and substituted dialkynes 11−14 in DMEM.
This in situ stapling technique allowed the screening of the
resultant stapled peptides directly in the cellular medium and
avoided the need to perform separate stapling reactions and
puriﬁcations with each dialkyne variant. This assay also showed
meta-ﬂuoro-functionalized peptide 22 (fold activation: 3.9 ±
0.7) to be themost potent and twice as active than unsubstituted
Scheme 2. Application of Fluoro- andMethoxy-Substituted SondheimerDialkynes 11−14 in Double Strain-Promoted Stapling of
p53-Based Diazidopeptide 2 To Generate Functionalized Stapled Peptide Inhibitors 22−25 of p53-MDM2 PPIa
aThe yields depicted are the isolated yields of the major fraction of the stapled peptides obtained after HPLC puriﬁcation. The major isomer of the
functionalized stapled peptides separated by HPLC puriﬁcation was tested for biological activity.
Table 1. In Vitro Binding Aﬃnity of Functionalized Stapled
Peptides for MDM2 by Fluorescence Polarization
functionalized stapled peptide Kd (nM)
22 17.3 ± 7.70
23 501 ± 107
24 8.50 ± 1.90
25 130 ± 28.3
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stapled peptide 26 (fold activation: 1.9 ± 0.1, Figure 2b). No
p53 activation was observed with dialkynes 12, 13, and 14.
Kinetic Analysis. To determine the eﬀect of substitution on
the azide-reactivity of Sondheimer dialkyne 1, we experimentally
investigated the SPAAC reactivity of our substituted Sond-
heimer dialkynes bearing substituents at ortho- and meta-
positions relative to the alkyne moiety (Figure 3). We studied
the reaction kinetics of 11 and 12 by monitoring their
consumption in a SPAAC with benzyl azide in methanol using
UV spectroscopy (see Supporting Information 1.4 for details).
We also compared the kinetic data of ortho- and meta-amine-
substituted dialkynes 27−32, available from our previous studies
(Figure 3, see Supporting Information 1.4 for details).19 The
second-order rate constants determined experimentally are
depicted in Figure 3.
We observed that the presence of a substituent at the ortho-
position led to a signiﬁcant decrease in the rate of reaction of 1. A
ﬂuoro-substituent at the meta-position (11, 0.047 M−1 s−1) did
not have any considerable eﬀect on the rate of reaction of 1. On
the other hand, a ﬂuoro-substituent at the ortho-position (12,
0.004 M−1 s−1) resulted in about ten-fold decrease in the rate of
reaction compared to 11 and 1. Moreover, the presence of a
larger dimethylamine substituent ortho to the alkyne (30) led to
a further decrease in reactivity, making it essentially unreactive
toward benzyl azide at rt.19 Similarly, dialkynes bearing a
charged trimethylammonium substituent at the ortho-position
(31 and 32) were also found to be unreactive.19 Overall,
trimethylammonium-substituted dialkyne 29 was found to be
the most reactive dialkyne exhibiting 3.6-fold increase in
reactivity over Sondheimer dialkyne 1.
X-ray Crystallographic and Computational Analysis.
In order to understand the observed contrast in reactivity
between the ortho and meta-substituted dialkynes, we
successfully determined the X-ray crystal structures of amine-
substituted dialkynes 27, 28, 29, and 30 (Figure 4a). Previously,
Bertozzi and co-workers have demonstrated how alkyne bond
angles in strained cyclooctyne reagents can be used as a measure
to predict their reactivity.20 Hence, we sought to determine how
the presence of diﬀerent substituents at ortho and meta-position
would aﬀect structural changes in our substituted Sondheimer
dialkynes. Alkyne bond angles measured experimentally via X-
ray crystallography for 27−30 are depicted in parenthesis in
Figure 4b. From the resulting structural data obtained, we noted
Figure 2. (a) p53 activation in the cellular reporter assay with
prestapled puriﬁed peptides 22−25. (b) p53 activation in a cellular
reporter assay for in situ stapling of 2 (50 μM) with substituted
dialkynes 11, 12, 13, 14, and dialkyne 1 (0.5 mM) in parallel, giving
stapled peptides 22, 23, 24, 25, and 26, respectively (performed as
technical triplicate). Data is reported as fold activation over 1% DMSO.
Figure 3. Experimentally determined second-order rate constants (k, in M−1 s−1) of substituted Sondheimer dialkynes in SPAAC with benzyl azide in
MeOH at rt.
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that the presence of a dimethylamine substituent at either the
ortho or meta-position (30 and 27) did not aﬀect any signiﬁcant
structural change on Sondheimer dialkyne 1 (Figure 4b). A
charged trimethylammonium substituent (28) at the meta-
position, however, did aﬀect minor structural changes on the
dialkyne distorting the alkyne bond angles slightly, reﬂecting an
increased reactivity.
Concurrently, we also performed a computational analysis to
predict the alkyne bond angles of our amine and ﬂuoro
substituted dialkynes 11, 12, 27−30 (Figure 4b). All geometry
optimizations were performed using Gaussian 0921 with the
B3LYP density functional and the 6-31G(d) basis set within the
CPCMmodel for methanol as the solvent at standard conditions
(see Supporting Information 2 for full computational de-
tails).8,20,22,23 Single-point energies were calculated using M06-
2X,24 the polarized, triple-ζ valence quality def2-TZVPP basis
set of Weigend and Ahlrichs,25 and an ultraﬁne integration grid
within the CPCM model (methanol). The Gibbs free energy
values were determined by the addition of the B3LYP thermal
correction to the M06-2X energies.26 This approach has
previously been shown to give reliable results when modeling
organic reactions.27,28 The computationally obtained geometry
optimized structures of the substituted dialkynes 27−30
corroborated with the X-ray crystal structures (see Supporting
Information 1.5 and 2.1.1 for details). Furthermore, these
studies indicated that the presence of a ﬂuoro substituent at the
ortho or meta-position (12 and 11) did not result in any
signiﬁcant structural change on Sondheimer dialkyne 1 (Figure
4b). We also calculated the strain energies for these substituted
Sondheimer dialkynes in accordance with the work previously
reported by Orita and co-workers (Figure 4b, see Supporting
Information 2.2 for details).15 We found that all of the
substituted dialkynes show similar values of strain energy.
Generally, we noted that the substitution of Sondheimer
dialkyne 1 did not result in any signiﬁcant structural change and
all substituted dialkynes demonstrated alkyne bond angles
around 155°, along with similar strain energy values. This
suggested that alkyne bond angle distortion and strain energy are
not the sole factors determining the reactivity of these
substituted strained alkynes and that there are other potential
factors like steric and electronic eﬀects playing a role.
Figure 4. Structural analysis of substituted Sondheimer dialkynes. (a)
X-ray crystal structures of dialkynes 27, 28, 29, and 30. (b) Calculated
bond angles and strain energy values (X-ray crystallography data shown
in parenthesis).
Figure 5. (a) Transition-state structures and activation free energies in kcal/mol for cycloaddition of substituted Sondheimer dialkynes with methyl
azide in methanol. (b) Front view of the transition states of cycloaddition with dialkynes 1, 12, and 30 depicting C−N bond lengths. (c) Side view of
the transition states depicting the angle of the azide approach during cycloaddition with dialkynes 1, 12, and 30.
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Therefore, to further investigate the eﬀect of the substituent
on the reactivity of our amine and ﬂuoro-substituted
Sondheimer dialkynes 11, 12, 27−30, we calculated their
transition state barriers in a SPAAC with methyl azide (Figure
4a). Previously, Goddard and co-workers have computationally
predicted a decrease in reactivity for dibenzocyclooctynes over
cyclooctynes due to the resulting steric interference between the
incoming azide and hydrogen atom on the benzene ring ortho to
the alkyne.29 A similar decrease in the reactivity in the presence
of an ortho-substituent has also been observed by Bertozzi and
co-workers with biarylazacyclooctynone (BARAC)-based al-
kynes.20
We started our investigations with Sondheimer dialkyne 1 and
calculated the transition states for both ﬁrst and second
cycloaddition with methyl azide in MeOH at rt. We chose
methyl azide as it is less conformationally ﬂexible than benzyl
azide, and calculations show that it behaves similarly to benzyl
azide in a SPAACwith 1.20 We found that the ﬁrst cycloaddition
leading to the formation of the monoyne intermediate is the
rate-determining step because the second cycloaddition
demonstrated a lower activation energy barrier than the ﬁrst
(by 3.6 kcal/mol, see Supporting Information Figures S86 and
S94 for details). This is in accordance with the results obtained
by Hosoya and co-workers for the SPAAC of Sondheimer
dialkyne 1 with methyl azide.8 Therefore, we calculated the
transition states and activation barriers of the ﬁrst cycloaddition
for all of our substituted Sondheimer dialkynes (Figure 5a).
Transition states were found for both anti- and syn-attack (see
Supporting Information 2.1.3 for details) of methyl azide on
dialkynes, we denote here the one with the lower activation
barrier for rate comparison.
We found that substitution of Sondheimer dialkyne with a
ﬂuoro group at the meta-position 11 led to a small decrease in
the activation barrier (by 0.6 kcal/mol), whereas substitution
with dimethylamine at meta-position 27 led to a small increase
in the activation barrier (by 0.5 kcal/mol). However,
substitution with either a ﬂuoro 12 or dimethylamine 30 at
the ortho-position led to large increments in the activation
barrier (by 1.1 and 2.3 kcal/mol, respectively), thereby
suggesting a decreased SPAAC reactivity. This increase in the
SPAAC activation barrier of Sondheimer dialkyne in the
presence of an ortho-substituent was found to be more
signiﬁcant with the bulkier dimethylamine substituent 30 in
comparison to ﬂuoro 12. This was clearly reﬂected in their
relative SPAAC rates observed experimentally (Figure 3).
We further analyzed the transition states of ortho-substituted
dialkynes 12 and 30 in order to explain their observed inactivity
(Figure 5b,c). This demonstrated that the presence of a bulkier
dimethylamine substituent in 30 leads to an increased C−N
bond distance (by 0.2 Å) on one side in the transition state
(Figure 5b). This is consistent with the observation made by
Bertozzi and co-workers with ortho-substituted BARAC.20 The
presence of a relatively smaller ﬂuoro substituent at the ortho-
position in 12 similarly resulted in a small increase in the C−N
bond distance (by 0.1 Å). We also looked at the approach of the
methyl azide toward dialkynes 12 and 30, and we noticed from
the transition states (side-view) that as the size of the ortho-
substituent increases, the angle of attack (from the plane of
dialkyne) increases (Figure 5c). These observations conﬁrm
that the presence of an ortho-substituent on Sondheimer
dialkyne hinders the approach of methyl azide during cyclo-
addition, and the larger the substituent the more signiﬁcant is
the eﬀect. Conversion of meta-dimethylamine-substituted
dialkyne 27 to monocharged 28 led to a decrease in the
cycloaddition barrier (by 0.8 kcal/mol), suggesting an increase
in rate of reaction (Figure 6a). This was further decreased (by
0.6 kcal/mol) on conversion to the bis-charged 29, suggesting a
further increase in the reactivity. This was in accordance with
their relative rates of reaction observed experimentally.
In order to further explain the relative reactivities observed
with substituted Sondheimer dialkynes, we applied the
distortion/interaction (D/I) model developed by Ess and
Houk co-workers to selected substrates.30,31 This model
deconstructs the activation energy ΔEact⧧ into distortion energy
ΔEdist⧧ and interaction energy ΔEint⧧ (Figure 6a). Distortion
energy is the energy needed to distort the starting alkyne and
azide to transform them into their preferred transition-state
geometries, whereas the interaction energy is the energy released
upon favorable orbital interactions between these distorted
reactants. This model has previously been applied to various
SPAAC reaction systems, and it has been generally observed that
steric eﬀects induced by the presence of a substituent are
reﬂected in an increased distortion energy, whereas the
interaction energy encompasses the electronic eﬀects intro-
duced by the substituent.20,23,32 Hence, we used this model to
calculate the distortion (ΔEdist⧧ ) and interaction energies (ΔEint⧧ )
for our reaction in order to investigate the steric and electronic
eﬀects of diﬀerent substituents on Sondheimer dialkyne SPAAC
reactivity.
Figure 6. (a) Application of D/I analysis on SPAAC of methyl azide
with substituted Sondheimer dialkynes. (b) Table depicting calculated
distortion energies (ΔEdist⧧ ), interaction energies (ΔEint⧧ ), overall
electronic energies of activation (ΔE⧧), and free energies of activation
(ΔG⧧). ΔEdist⧧ , ΔEint⧧ , and ΔE⧧ denoted here are calculated using the
single-point energies obtained with M06-2X,24 the polarized, triple-ζ
valence quality def2-TZVPP basis set of Weigend and Ahlrichs,25 and
an ultraﬁne integration grid within the CPCM model (methanol).
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The results from D/I analysis (Figure 6b) demonstrated that
the presence of an ortho-substituent next to the alkyne has a
signiﬁcant eﬀect on the distortion energy. For instance,
installation of an ortho-ﬂuoro (12) caused an increase in the
distortion energy ΔEdist⧧ (by 1.3 kcal/mol) and a slight increase
in the interaction energy ΔEint⧧ (by 0.4 kcal/mol), leading to an
overall increase in the activation energy ΔE⧧ (by 0.9 kcal/mol).
The most signiﬁcant eﬀect was observed with the bulkier
dimethylamine substituent at the ortho-position (30), which led
to a considerable increase in the distortion energyΔEdist⧧ (by 1.8
kcal/mol) and no change in the interaction energy, leading to an
even higher overall activation barrier ΔE⧧ (by 1.8 kcal/mol).
This clearly reﬂects the steric hindrance oﬀered to the SPAAC
reaction in the presence of an ortho-substituent which becomes
more signiﬁcant in the presence of an even bulkier substituent,
overall resulting in an observed sluggish reactivity of these
dialkynes. This is also in accordance with the D/I analysis results
shown previously with BARAC in the presence of an ortho-
ﬂuoro/methyl substituent.20 On the other hand, installation of a
substituent at the meta-position of Sondheimer dialkyne (11
and 27) did not have a considerable eﬀect on the D/I energetics.
■ CONCLUSIONS
In conclusion, we have reported the synthesis of substituted
variants of the Sondheimer dialkyne and their application in the
double strain-promoted stapling of a p53-based diazido peptide
2 to generate four novel functionalized stapled peptide
inhibitors of the oncogenic p53-MDM2 PPI. Minor changes
in the aromatic substitution pattern around the aromatic rings of
the stapled peptides were found to aﬀect both MDM2 binding
aﬃnity and p53 cellular activity. The ﬂuoro-functionalized
stapled peptide 22was found to be the most potent inhibitor in a
p53-reporter cell-based assay. Overall, this study demonstrates
that substituted Sondheimer dialkynes can be employed in
double strain-promoted stapling as a means to readily access
functionally diverse stapled peptides. In the future, this approach
could conceivably be used to develop potent functionalized
stapled peptide inhibitors of other therapeutically relevant PPIs.
Reactivity investigations, through experimental studies and
density functional theory calculations, suggested the involve-
ment of steric and electronic eﬀects induced by the substituent
in determining the reactivity of the substituted Sondheimer
dialkyne.
■ EXPERIMENTAL SECTION
General. Solvents and Reagents. Tetrahydrofuran was
dried over sodium wire and distilled from a mixture of calcium
hydride and lithium aluminium hydride with triphenylmethane
as the indicator. Diethyl ether was distilled from a mixture of
calcium hydride and lithium aluminium hydride. Dichloro-
methane, methanol, hexane, acetonitrile, and toluene were
distilled from calcium hydride. Petroleum ether refers to the
fraction of petroleum ether boiling in the range 40−60 °C. All
other reagents and solvents were used as supplied, without prior
puriﬁcation.
Chromatography. Flash column chromatography was
carried out using Kieselgel 60 silica (230−400 mesh) with
distilled solvents under a positive pressure of nitrogen. Thin-
layer chromatography was carried out on glass Merck Kieselgel
60 F254 plates, visualized by ultraviolet irradiation (254 and 365
nm)
NMR Spectroscopy.NMR spectra were recorded on a Bruker
Ultrashield 500 (1H: 500 MHz and 13C: 126 MHz)
spectrometer. Chemical shifts are quoted in ppm and are
referenced to the residual nondeuterated solvent peak and are
reported based on the appearance rather than interpretation. 1H
spectra are reported as follows: δH (spectrometer frequency,
solvent): ppm (no. of protons, multiplicity, J-coupling
constant(s), assignment). 13C spectra are reported as follows:
δC (spectrometer frequency, solvent): ppm (assignment).
Spectral assignment was aided by the results of DEPT, COSY,
HMBC, and HSQC experiments where appropriate.
IR Spectroscopy. IR spectra were recorded neat on a
PerkinElmer Spectrum One FT-IR spectrophotometer ﬁtted
with an attenuated total reﬂectance sampling accessory.
Absorption maxima are reported in wavenumbers (cm−1).
High Resolution Mass Spectrometry. Accurate masses were
recorded on a Waters LCT Premier Time of Flight mass
spectrometer or Micromass Quadrupole-Time of Flight mass
spectrometer. Reported mass values are within the error limits of
±5 ppm.
Liquid Chromatography−Mass Spectrometry. Liquid
chromatography−mass spectrometry chromatographs were
obtained on an Agilent 1200 series LC using a Supelcosil ABZ
+ PLUS column (33 mm × 4.6 mm, 3 μm), together with an
ESCi Multi-Mode Ionisation Waters ZQ spectrometer using
MassLynx 4.1 software. Chromatographs were monitored by
absorbance using diode array detection at a wavelength range of
190−600 nm.
High-Performance Liquid Chromatography. Analytical
high-performance liquid chromatography (HPLC) chromato-
graphs were obtained on an Agilent 1260 Inﬁnity, eluting with a
gradient of 5−40% MeCN (with 0.05% TFA) in water (with
0.1% TFA) over 15 min. Semi-preparative HPLC was run on an
Agilent 1260 Inﬁnity, eluting with a gradient of 5−65% MeCN
(with 0.05% TFA) in water (with 0.1% TFA) over 20 min.
Retention times are reported to the nearest 0.01 min.
Melting Points. All melting points were measured on a Büchi
B545 melting point apparatus and are uncorrected. Solvents are
reported in parentheses where solids were puriﬁed by
recrystallization.
Naming and Numbering of Compounds. Where given,
systematic compound names are those generated by ChemBio-
Draw Ultra 13.0 following IUPAC conventions. The numbering
of atoms for spectral assignment purposes is arbitrary and not
necessarily consistent with the IUPAC name.
Synthet i c P rocedures . Methy l 4 -F luo ro -2 -
((phenylsulfonyl)methyl)benzoate 16. To a suspension of
methyl 4-ﬂuoro-2-methylbenzoate 15 (2.0 g, 11.89 mmol) in
CCl4 (59 mL) at 80 °C under N2 were addedNBS (2.23 g, 12.49
mmol) and AIBN (0.19 g, 1.19 mmol), and then the resulting
mixture was heated at 100 °C. After stirring at this temperature
for 6 h, the reaction mixture was cooled to rt. The reaction
mixture was diluted with saturated aqueous NH4Cl (60mL) and
extracted with CH2Cl2 (3 × 60 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo.
To the resulting crude product (3.23 g, 13.07mmol) were added
benzenesulﬁnic acid sodium salt dihydrate (2.58 g, 15.71 mmol)
and DMF (20 mL). After the resulting mixture had been stirred
at 80 °C overnight, it was cooled to rt. The reaction mixture was
diluted with water (40 mL) and extracted with EtOAc (3 × 40
mL). The organic layers were combined, dried (MgSO4),
ﬁltered, and concentrated in vacuo. Puriﬁcation via ﬂash column
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chromatography on silica gel (PE/Et2O = 2:1) gave 16 (2.57 g,
70%) as a white solid.
mp 122−124 °C. νmax (neat): 2954 (C−H), 1717 (CO),
1589, 1306 (SO), 1273, 1252, 1151 (SO), 1117. δH (500
MHz, CDCl3): 7.93 (1H, dd, J 8.52, 5.81, Ar H), 7.71−7.65
(2H, m, Ar H), 7.62 (1H, t, J 7.47, Ar H), 7.52−7.43 (2H, m, Ar
H), 7.14−7.04 (2H, m, Ar H), 5.04 (2H, s, H6), 3.74 (3H, s,
H11). δC (126 MHz, CDCl3): 166.1 (C12), 164.2 (d, J 255.14,
C3), 138.2 (Ar C), 133.7 (Ar CH), 133.5 (d, J 9.02, Ar CH),
132.4 (d, J 8.76, Ar CH), 128.9 (Ar CH), 128.6 (Ar CH), 126.8
(Ar C), 120.4 (d, J 22.68, Ar CH), 115.9 (d, J 21.14, Ar CH),
58.9 (C6), 52.2 (C11). δF (376 MHz, CDCl3): −105.7. HRMS
(ES+): found 309.0584; C15H14O4F
32S [M + H]+, requires
309.0597.
(4-Fluoro-2-((phenylsulfonyl)methyl)phenyl)methanol 17.
To a solution of 16 (2.48 g, 8.04 mmol) in CH2Cl2 (24.1 mL)
was added DIBAL-H (1.0 M in hexane, 18.5 mL, 18.5 mmol) at
−78 °C. After the mixture had been stirred at this temperature
for 2 h, saturated aqueous NH4Cl (100 mL) was poured into the
mixture followed by 1 M HCl (100 mL). The product was then
extracted with CH2Cl2 (3 × 200 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo
to aﬀord the pure product 17 as a white solid (2.04 g, 90%).
mp 145−149 °C. νmax (neat): 3479 (O−H), 1592, 1499,
1447, 1305 (SO), 1146 (SO), 1081. δH (500 MHz,
CDCl3): 7.80−7.74 (2H, m, Ar H), 7.69 (1H, t, J 7.69, Ar H),
7.59−7.51 (2H, m, Ar H), 7.41 (1H, dd, J 8.49, 5.77, H1), 7.05
(1H, td, J 8.29, 2.67, H2), 6.68 (1H, dd, J 9.17, 2.66, H4), 4.61
(2H, s, H12), 4.50 (2H, s, H6), 2.61 (1H, br s, H11). δC (126
MHz, CDCl3): 161.8 (d, J 247.68, C3), 137.8 (Ar C), 136.9 (Ar
C), 134.3 (Ar CH), 132.2 (d, J 8.24, C1), 129.3 (Ar CH), 128.6
(Ar CH), 128.2 (d, J 7.97, Ar C), 119.2 (d, J 22.66, C4), 116.4
(d, J 20.77, C2), 62.5 (C12), 59.4 (C6). δF (376 MHz, CDCl3):
−113.4. HRMS (ES+): found 303.0465; C14H13O3F32SNa [M +
Na]+, requires 303.0462.
4-Fluoro-2-((Phenylsulfonyl)methyl)benzaldehyde 3. To a
solution of 17 (2.08 g, 7.42 mmol) in CH2Cl2 (22.0 mL) was
added DMP (3.46 g, 8.16 mmol) at rt. After the reaction mixture
had been stirred for 3 h, the reaction mixture was diluted with
CH2Cl2 (15 mL) and poured into saturated Na2S2O3 solution
(30 mL). The mixture was stirred to dissolve the solid, and the
layers were separated. The CH2Cl2 layer was then extracted with
saturated aqueous Na2S2O3 (2 × 30 mL) followed by saturated
aqueous NaHCO3 (2 × 30 mL). CH2Cl2 was then removed in
vacuo, and puriﬁcation via ﬂash column chromatography on
silica gel (EtOAc/hexane = 1:2) gave pure product 3 (1.3 g,
63%) as a white solid.
mp 138−140 °C. νmax (neat): 2988, 1693 (CO), 1585,
1447, 1306 (SO), 1238, 1150 (SO), 1083. δH (400 MHz,
CDCl3): 9.81 (1H, s, H11), 7.82−7.72 (3H, m, Ar H), 7.65 (1H,
t, J 7.48, Ar H), 7.54−7.46 (2H, m, Ar H), 7.32−7.18 (2H, m, Ar
H), 5.04 (2H, s, H6). δC (126 MHz, CDCl3): 190.4 (C11),
165.0 (d, J 258.44, C3), 138.1 (Ar C), 137.1 (d, J 9.92, Ar CH),
134.1 (Ar CH), 132.2 (d, J 9.39, Ar C), 131.3 (d, J 3.08, Ar C),
129.0 (Ar CH), 128.6 (Ar CH), 121.1 (d, J 22.97, C4), 116.6 (d,
J 21.60, Ar CH), 57.2 (C6). δF (376 MHz, CDCl3): −102.3.
HRMS (ES+): found 279.0489; C14H12O3
32SF [M + H]+,
requires 279.0491.
(5E,11E)-2,8-Diﬂuoro-6,12-bis(phenylsulfonyl)dibenzo-
[a,e][8]annulene 7. A mixture of 3 (0.80 g, 2.88 mmol) and
ClP(O) (OEt)2 (0.5 mL, 3.46 mmol) in THF (58 mL) was
cooled to −78 °C, and then LiHMDS (1.0 M in THF, 5.8 mL,
5.8 mmol) was added. After stirring at −78 °C for 30 min, the
reaction mixture was warmed to rt and stirred for a further 1.5 h.
Saturated aqueous NH4Cl (8 mL) was poured into the mixture.
The reaction mixture was diluted with water (90 mL) and
extracted with EtOAc (3 × 100 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation via ﬂash column chromatography on silica gel
(EtOAc/hexane = 3:8) gave 7 as a pale yellow solid (0.28 g,
19%).
mp 203 °C (dec.). νmax (neat): 2923, 1579, 1493, 1447, 1319
(SO), 1222, 1151 (SO), 1084. δH (500MHz, CDCl3): 7.66
(2H, t, J 7.19, Ar H), 7.54−7.44 (8H, m, Ar H), 7.33 (2H, s, Ar
H), 7.21 (2H, dd, J 9.33, 2.50, Ar H), 7.06−6.94 (4H, m, Ar H).
δC (126 MHz, CDCl3): 162.0 (d, J 250.77, C3), 144.4 (Ar C),
138.6 (Ar CH), 136.6 (Ar C), 134.1 (Ar CH), 131.2 (Ar C),
131.1 (d, J 8.80, Ar C), 129.1 (Ar CH), 128.9 (d, J 8.59, Ar CH),
128.1 (Ar CH), 117.9 (d, J 23.49, Ar CH), 117.1 (d, J 21.88, Ar
CH). δF (376 MHz, CDCl3): −110.6. HRMS (ES+): found
521.0704; C28H19F2O4
32S2 [M + H]
+, requires 521.0693.
2,8-Diﬂuoro-5,6,11,12-tetradehydrodibenzo[a,e]-
cyclooctene 11. A solution of 7 (0.11 g, 0.21 mmol) in THF
(5.3 mL) was cooled to−78 °C, and then LDA (1.0 M in THF/
hexane, 0.85 mL, 0.85 mmol) was added. The reaction mixture
was stirred at this temperature for 2 h, and saturated aqueous
NH4Cl (9 mL) was poured into the mixture. The reaction
mixture was cooled to rt, diluted with water (25 mL), and
extracted with CH2Cl2 (3 × 35 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation via ﬂash column chromatography on silica gel
(EtOAc/hexane = 1:8) gave 11 as a yellow solid (15 mg, 30%).
νmax (neat): 2922, 1569, 1461, 1243, 977, 778. δH (500 MHz,
CDCl3): 6.98−6.91 (2H, m, Ar H), 6.73 (2H, t, J 8.74, Ar H),
6.59 (2H, d, Ar H). δC (126 MHz, CDCl3): 158.6 (d, J 254.49,
C3), 134.3 (Ar C), 131.0 (d, J 8.54, Ar CH), 123.2 (d, J 2.93, Ar
CH), 119.8 (d, J 16.54, Ar C), 117.8 (d, J 21.06, Ar CH), 111.4
(CC), 104.9 (CC). δF (376MHz, CDCl3):−107.7. HRMS
(ES+): found 236.0428; C16H6F2 [M + H]
+, requires 236.0438.
3-Fluoro-2-((phenylsulfonyl)methyl)benzonitrile 20. To a
suspension of 3-ﬂuoro-2-methylbenzonitrile 18 (5.28 g, 39.1
mmol) in CCl4 (196.0 mL) at 80 °C under N2 were added NBS
(7.31 g, 41.06 mmol) and AIBN (0.64 g, 3.91 mmol), and then
the resulting mixture was heated at 100 °C. After stirring at this
temperature for 6 h, the reaction mixture was cooled to rt. The
reaction mixture was diluted with saturated aqueous NH4Cl
(150 mL) and extracted with CH2Cl2 (3 × 150 mL). The
organic layers were combined, dried (MgSO4), ﬁltered, and
concentrated in vacuo. To the resulting crude product (8.63 g,
40.33 mmol) were added benzenesulﬁnic acid sodium salt
dihydrate (7.94 g, 48.4 mmol) and DMF (60.5 mL). After the
resulting mixture had been stirred at 80 °C overnight, it was
cooled to rt. The reaction mixture was diluted with water (100
mL) and extracted with EtOAc (3 × 100 mL). The organic
layers were combined, dried (MgSO4), ﬁltered, and concen-
trated in vacuo. Puriﬁcation via ﬂash column chromatography
on silica gel (PE/Et2O = 2:1) gave 20 (6.56 g, 61%) as a white
solid.
mp 156−158 °C. νmax (neat): 2236 (CN), 1575, 1321 (S
O), 1253, 1137 (SO), 1084. δH (500 MHz, CDCl3): 7.84−
7.78 (2H, m, Ar H), 7.70 (1H, t, J 7.49, Ar H), 7.59−7.52 (2H,
m, Ar H), 7.51−7.45 (2H, m, Ar H), 7.39−7.31 (1H, m, Ar H),
4.63 (2H, s, H6). δC (126 MHz, CDCl3): 161.4 (d, J 254.59,
C4), 138.0 (Ar C), 134.5 (Ar CH), 131.5 (d, J 8.98, Ar CH),
129.4 (Ar CH), 129.1 (d, J 3.85, Ar CH), 128.7 (Ar CH), 120.7
(d, J 22.15, Ar CH), 119.7 (d, J 17.48, Ar C), 116.3 (CN), 115.6
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(Ar C), 55.0 (C6). δF (376 MHz, CDCl3): −109.8. HRMS
(ES+): found 276.0498; C14H11NO2
32SF [M + H]+, requires
276.0495.
(5E,11E)-1,7-Diﬂuoro-6,12-bis(phenylsulfonyl)dibenzo-
[a,e][8]annulene 8. To a solution of 20 (1.06 g, 3.88 mmol) in
CH2Cl2 (19.4 mL) was added DIBAL-H (1.0 M in hexane, 7.77
mL, 7.77 mmol) at−78 °C. After the mixture had been stirred at
this temperature for 2 h, saturated aqueous NH4Cl (50 mL) was
poured into the mixture followed by 1 M HCl (50 mL). The
product was then extracted with CH2Cl2 (3 × 100 mL). The
organic layers were combined, dried (MgSO4), ﬁltered, and
concentrated in vacuo. Puriﬁcation via ﬂash column chromatog-
raphy on silica gel (EtOAc/hexane = 1:2) gave 4 (0.70 g, 65%)
as a crude white solid consisting of an inseparable mixture of the
desired aldehyde product (major) and the starting material. A
mixture of crude 4 (0.52 g, 1.85 mmol) and ClP(O) (OEt)2
(0.32 mL, 2.23 mmol) in THF (37 mL) was cooled to −78 °C,
and then LiHMDS (1.0 M in THF, 3.71 mL, 3.71 mmol) was
added. After stirring at −78 °C for 30 min, the reaction mixture
was warmed to rt and stirred for a further 1.5 h. Saturated
aqueous NH4Cl (5 mL) was poured into the mixture. The
reaction mixture was diluted with water (50 mL) and extracted
with EtOAc (3 × 60 mL). The organic layers were combined,
dried (MgSO4), ﬁltered, and concentrated in vacuo. Puriﬁcation
via ﬂash column chromatography on silica gel (EtOAc/hexane =
3:8) gave 8 as a pale yellow solid (0.22 g, 23%).
mp 190−193 °C. νmax (neat): 1571, 1446, 1319 (SO),
1260, 1146 (SO), 1085. δH (500MHz, CDCl3): 7.67 (2H, t, J
7.11), 7.57−7.46 (10H, m, Ar H), 7.33−7.27 (2H, m, Ar H),
6.95−6.86 (4H, m, Ar H). δC (126 MHz, CDCl3): 160.2 (d, J
253.97, C4), 142.7 (Ar C), 140.6 (Ar CH), 138.5 (Ar C), 138.0
(Ar C), 134.0 (Ar CH), 131.5 (d, J 8.80, Ar CH), 129.2 (Ar
CH), 128.6 (Ar CH), 122.6 (Ar CH), 117.4 (d, J 17.06, Ar C),
116.3 (d, J 21.80, Ar CH). δF (376 MHz, CDCl3): −105.5.
HRMS (ES+): found 521.0693; C28H19O4
32S2F2 [M + H]
+,
requires 521.0693.
1,7-Diﬂuoro-5,6,11,12-tetradehydrodibenzo[a,e]-
cyclooctene 12. A solution of 8 (0.13 g, 0.24 mmol) in THF
(4.9 mL) was cooled to−78 °C, and then LDA (1.0 M in THF/
hexane, 0.98 mL, 0.98 mmol) was added. The reaction mixture
was stirred at this temperature for 2 h, and saturated aqueous
NH4Cl (7 mL) was poured into the mixture. The reaction
mixture was cooled to rt, diluted with water (20 mL), and
extracted with CH2Cl2 (3 × 30 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation via ﬂash column chromatography on silica gel
(EtOAc/hexane = 1:8) gave 12 as a yellow solid (15 mg, 26%).
mp 140 °C (dec.). νmax (neat): 2156 (CC), 1574, 1448,
1181, 877, 815. δH (500 MHz, CDCl3): 6.74−6.68 (2H, m, Ar
H), 6.62 (2H, td, J 8.41, 2.61, Ar H), 6.48 (2H, dd, J 8.70, 2.60,
Ar H). δC (126MHz, CDCl3): 163.0 (d, J 250.97, C4), 135.3 (d,
J 10.12), 128.2 (d, J 8.78, Ar CH), 115.22 (Ar CH), 115.23 (d, J
45.55, Ar C), 109.9 (CC), 107.4 (CC). δF (376 MHz,
CDCl3):−109.5. HRMS (ES+): found 236.0427; C16H6F2 [M +
H]+, requires 236.0438.
4-Methoxy-2-((phenylsulfonyl)methyl)benzonitrile 21. To
a suspension of 4-methoxy-2-methylbenzonitrile 19 (4.00 g,
27.21 mmol) in CCl4 (80.0 mL) at 80 °C under N2 were added
NBS (5.81 g, 32.65 mmol) and benzoyl peroxide (329 mg, 1.36
mmol), and then the resulting mixture was heated at 80 °C. After
stirring at this temperature for 6 h, the reaction mixture was
cooled to rt. The reaction mixture was diluted with saturated
aqueous NH4Cl (80 mL) and extracted with CH2Cl2 (3 × 80
mL). The organic layers were combined, dried (MgSO4),
ﬁltered, and concentrated in vacuo. To the resulting crude
product were added benzenesulﬁnic acid sodium salt dihydrate
(6.69 g, 40.82 mmol) and DMF (80.0 mL). After the resulting
mixture had been stirred at 80 °C overnight, it was cooled to rt.
The reaction mixture was diluted with water (100 mL) and
extracted with EtOAc (3 × 100 mL). The organic layers were
combined, dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation via ﬂash column chromatography on silica gel
(EtOAC/hexane = 1:2) gave 21 (6.24 g, 81%) as a white solid.
mp 144−145 °C. νmax (neat): 2944, 2221 (CN), 1609,
1499, 1291 (SO), 1147 (SO), 1082, 1025. δH (500 MHz,
CDCl3): 7.73 (2H, dd, J 8.4, 1.2, H8), 7.69−7.62 (1H, m, H10),
7.53−7.47 (2H, m, H9), 7.44 (1H, d, J 8.7, H1), 7.10 (1H, d, J
2.5, H4), 6.93 (1H, dd, J 8.7, 2.5, H2), 4.52 (2H, s, H6), 3.87
(3H, s, H13). δC (126 MHz, CDCl3): 162.8 (C3), 137.7 (C7),
134.4 (Ar CH), 134.4 (Ar CH), 133.8 (C12), 129.4 (C9), 128.8
(C8), 117.4 (C4), 117.1 (C11), 115.7 (C2), 106.0 (C5), 60.7
(C6), 55.9 (C13). HRMS (ES+): found 288.0686;
C15H14NO3
32S [M + H]+, requires 288.0689. Characterization
data is in accordance with that previously reported.33
4-Methoxy-2-((phenylsulfonyl)methyl)benzaldehyde 5.To
a solution of 21 (1.0 g, 3.48 mmol) in CH2Cl2 (10.0 mL) was
added DIBAL-H (1.0 M in hexane, 5.22 mL, 5.22 mmol) at−78
°C. After themixture had been stirred at this temperature for 2 h,
saturated aqueous NH4Cl (25 mL) was poured into the mixture,
followed by 1 M HCl (25 mL). The product was then extracted
with CH2Cl2 (3 × 50 mL). The organic layers were combined,
dried (MgSO4), ﬁltered, and concentrated in vacuo. Puriﬁcation
via ﬂash column chromatography on silica gel (EtOAc/hexane =
1:2) gave 5 (0.60 g, 59%) as a white solid.
δH (500MHz, CDCl3): 9.65 (1H, s, H11), 7.73−7.70 (2H, m,
H8), 7.63 (1H, d, J 8.5, H1), 7.62−7.57 (1H, m, H10), 7.48−
7.42 (2H, m, H9), 7.01 (1H, dd, J 8.5, 2.5, H2), 6.97 (1H, d, J
2.5, H4), 5.04 (2H, s, H6), 3.88 (3H, s, H13). δC (126 MHz,
CDCl3): 190.8 (C11), 163.4 (C3), 138.5 (C7), 137.4 (C1),
133.9 (C10), 131.4 (C12), 128.9 (C9), 128.8 (C8), 128.1 (C5),
119.5 (C4), 114.6 (C2), 57.7 (C6), 55.9 (C13). HRMS (ES+):
found 291.0683; C15H15O4
32S [M + H]+, requires 291.0686.
Characterization data is in accordance with that previously
reported.34
2,8-Dimethoxy-5,6,11,12-tetradehydrodibenzo[a,e]-
cyclooctene 13.Amixture of 5 (0.50 g, 1.72mmol) andClP(O)
(OEt)2 (0.30 mL, 2.07 mmol) in THF (35.0 mL) was cooled to
−78 °C, and then LiHMDS (1.0 M in THF, 3.79 mL, 3.79
mmol) was added. After stirring at −78 °C for 30 min, the
reaction mixture was warmed to rt and stirred for a further 1.5 h.
LDA (1.0 M in THF/hexane, 8.62 mL, 8.62 mmol) was then
added at −78 °C, and the reaction mixture was stirred at this
temperature for 2 h, and saturated aqueous NH4Cl (13.0 mL)
was poured into the mixture. The reaction mixture was diluted
with water (26.0 mL) and extracted with EtOAc (3 × 40 mL).
The organic layers were combined, dried (MgSO4), ﬁltered, and
concentrated in vacuo. Puriﬁcation via ﬂash column chromatog-
raphy on silica gel (EtOAc/hexane = 1:3) gave 13 as a yellow
solid (88 mg, 39%).
mp 171−173 (dec) °C. νmax (neat): 2916, 2849, 2145, 1595,
1562, 1421, 1318, 1213, 1065, 1024. δH (500 MHz, CDCl3):
6.67 (2H, d, J 8.4, Ar H), 6.39 (2H, dd, J 8.4, 2.6, Ar H), 6.34
(2H, d, J 2.6, Ar H), 3.72 (6H, s, H9). δC (126 MHz, CDCl3):
160.4 (C3), 135.0, 128.0 (C1), 124.0 (C8), 114.7 (C4), 112.0
(C2), 110.3 (CC), 107.4 (CC), 55.5 (C9). HRMS (ES+):
found 261.0904; C18H13O2 [M + H]
+, requires 261.0910.
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1,2-Dimethoxy-4-methyl-5-((phenylsulfonyl)methyl)-
benzene 33. A suspension of 3,4-dimethoxytoluene (1.52 g,
10.0 mmol) and paraformaldehyde (0.45 g, 15.0 mmol) in dry
CCl4 (16.6 mL) was cooled to 0 °C under N2. To this
suspension a solution of HBr/AcOH (33%, 4.0 mL) was added
dropwise over 3−5min, and the resulting mixture was stirred for
4 h at 0 °C. The reaction mixture was poured into cold water
(33.3 mL), and the organic layer was separated, washed with 5%
NaHCO3(aq), and dried over anhydrous MgSO4. Evaporation
of the solvents in vacuo aﬀorded a white solid. To this crude
product, benzenesulﬁnic acid sodium salt dihydrate (2.40 g, 12.0
mmol) and DMF (16.6 mL) were added. After stirring at 80 °C
overnight, the reaction mixture was cooled to rt. The reaction
mixture was diluted with water (30 mL) and extracted with
EtOAc (3 × 50 mL). The organic layers were combined, dried
(MgSO4), ﬁltered, and concentrated in vacuo. Puriﬁcation via
ﬂash column chromatography on silica gel (EtOAc/hexane =
1:8) gave 33 (2.63 g, 86%) as a white solid.
mp 158−160 °C. δH (500 MHz, CDCl3): 7.71−7.60 (3H, m,
H9, 11), 7.54−7.45 (2H, m, H10), 6.61 (1H, s, H14), 6.44 (1H,
s, H5), 4.31 (2H, s, H7), 3.86 (3H, s, H3), 3.68 (3H, s, H1), 2.05
(3H, s, H12). δC (126 MHz, CDCl3): 149.1 (C4), 146.8 (C2),
138.3 (C8), 133.7 (Ar CH), 131.0 (C6), 128.9 (Ar CH), 128.8
(Ar CH), 118.0 (C13), 114.4 (C5), 113.3 (C14), 59.9 (C7),
55.8 (C1, C3), 18.9 (C12). Characterization data is in
accordance with that previously reported.15
4,5-Dimethoxy-2-((phenylsulfonyl)methyl)benzaldehyde
6.To a suspension of 33 (1.22 g, 4.00 mmol) in CCl4 (37.0 mL)
at 80 °C under N2 were added NBS (0.75 g, 4.20 mmol) and
BPO (97.0 mg, 0.40 mmol), and then the resulting mixture was
heated at 100 °C. After stirring at this temperature for 6 h, the
reaction mixture was cooled to rt. After workup with CH2Cl2/
NH4Cl(aq), the combined organic layers were dried over
MgSO4 and evaporated in vacuo. To the resulting crude product
were added CaCO3 (4.0 g, 40.0 mmol), dimethoxyethane (13.3
mL), and H2O (13.3 mL). After the resulting mixture had been
heated at 120 °C overnight, it was cooled to rt, and the
remaining CaCO3 was neutralized with dilute HCl (aq)
solution. The reaction mixture was diluted with water (12
mL) and extracted with CH2Cl2 (3× 20mL). The organic layers
were combined, dried (MgSO4), ﬁltered, and concentrated in
vacuo. To this crude product were added MnO2 (3.48 g, 40.0
mmol) and CH2Cl2 (13.3 mL). After the resulting mixture was
heated to 50 °C overnight, it was cooled to rt and ﬁltered, and
the ﬁltrate was concentrated in vacuo. Puriﬁcation via ﬂash
column chromatography on silica gel (EtOAc/hexane = 1:1)
gave 6 as a pale-yellow solid (0.64 g, 50%).
mp 145−147 °C. δH (500 MHz, CDCl3): 9.76 (1H, s, H12),
7.71 (2H, dd, J 8.43, 1.18, Ar H), 7.66−7.61 (1H, m, Ar H),
7.51−7.46 (2H, m, Ar H), 7.26 (1H, s, H14), 6.80 (1H, s, H5),
4.92 (2H, s, H7), 3.96 (3H, s, H1), 3.91 (3H, s, H3). δC (126
MHz, CDCl3): 189.5 (C12), 153.0 (C2), 149.5 (C4), 137.9
(C8), 133.9 (Ar CH), 129.0 (Ar CH), 128.7 (Ar CH), 128.0
(C6), 123.7 (C13), 115.5 (C5), 114.1 (C14), 57.3 (C7), 56.3
(C3), 56.1 (C1). Characterization data is in accordance with
that previously reported.15
2,3,8,9-Tetramethoxy-5,6,11,12-tetradehydrodibenzo-
[a,e]cyclooctene 14. A mixture of 6 (185 mg, 0.58 mmol) and
ClP(O) (OEt)2 (0.10 mL, 0.69 mmol) in THF (11.5 mL) was
cooled to −78 °C, and then LiHMDS (1.0 M in THF, 1.15 mL,
1.15 mmol) was added. After stirring at −78 °C for 30 min, the
reaction mixture was warmed to rt and stirred for a further 1.5 h.
LDA (1.0 M in THF/hexane, 2.88 mL, 2.88 mmol) was then
added at −78 °C, and the reaction mixture was stirred at this
temperature for 2 h, and saturated aqueous NH4Cl (3 mL) was
poured into the mixture. The reaction mixture was diluted with
water (6 mL) and extracted with EtOAc (3 × 10 mL). The
organic layers were combined, dried (MgSO4), ﬁltered, and
concentrated in vacuo. Puriﬁcation via ﬂash column chromatog-
raphy on silica gel (PE/EtOAc = 1:1) gave 14 as a yellow solid
(41 mg, 22%).
mp 205 °C (dec.). δH (400 MHz, CDCl3): 6.26 (4H, s, H3),
3.78 (12 H, s, H1). δC (101 MHz, CDCl3): 149.0 (C2), 126.2
(C4), 111.4 (C3), 108.9 (C5), 56.2 (C1). Characterization data
is in accordance with that previously reported.15
Peptide Synthesis Procedure. Peptide synthesis was
carried out on solid-phase using an Fmoc-protecting group
strategy on a CEM Liberty Automated Microwave Peptide
Synthesizer. Merck Rink Amide MBHA resin LL (0.29−0.39
mmol/g) was used. Peptide couplings were conducted with
Fmoc-protected amino acids (5 equiv) in DMF, HATU, or
HBTU (5 equiv) in DMF as the coupling reagent, and N,N-
diisopropylethylamine (10 equiv) in NMP as the base. Double
coupling was used for arginine for 15 min each without
microwave irradiation. Single coupling was used for all other
amino acids, with 25 W power at 75 °C over 15 min. Fmoc
deprotection was carried out using 20% piperidine in DMF, with
45Wpower at 75 °C over 3min. N-terminal capping was carried
out manually by treating the resin-bound peptide with acetic
anhydride (10 equiv) and N,N-diisopropylethylamine (10
equiv) in dichloromethane for 45 min. Cleavage was carried
out with a cocktail of 95% triﬂuoroacetic acid, 2.5% water, and
2.5% triisopropylsilane for 2 h. The cleavage solution was then
evaporated under a stream of nitrogen and triturated with
diethyl ether prior to puriﬁcation by preparative HPLC. Peptide
yields were estimated based on absorbance in the HPLC
chromatograph at 220 nm. The concentration of peptides in
stock solutions was determined by amino acid analysis at the
Peptide Nucleic Acid Chemistry Facility at the Department of
Biochemistry, University of Cambridge.
General Strain-Promoted Double-Click Peptide Sta-
pling Procedure. A solution of diazido PDI-E peptide (1
equiv) and dialkyne (1.1 equiv) in 1:1 t-BuOH/H2O (1 mL/mg
peptide) was stirred at rt for 16 h. The reaction mixture was
lyophilized and puriﬁed by HPLC to give the stapled peptide.
Competitive Fluorescence Polarization Assay. Com-
petitive ﬂuorescence polarization (FP) assays were performed as
previously described2,7 in 384-well microplates (Corning) on a
CLARIOstar microplate reader (BMG labtech) using an
excitation ﬁlter 540−20 nm, dichroic mirror LP 566 nm, and
emission ﬁlter 590−20 nm. All peptides were dissolved in
DMSO as stock solutions. The stock concentration of the
TAMRA-labeled tracer (TAMRA-RFMDYWEGL-NH2) was
determined based on the 5-TAMRA absorbance at 556 nm
(extinction coeﬃcient ε = 89,000 M−1 cm−1) measured on a
NanoDrop 2000 (Thermo Scientiﬁc), and the concentrations of
all peptides were determined by amino acid analysis (Depart-
ment of Biochemistry, University of Cambridge). Kd of the
TAMRA-labeled tracer was obtained from previously reported
experiments.2 For the competitive ﬂuorescence polarization
assay, the TAMRA-labeled tracer (50 nM) was incubated with
MDM2 (95 nM) in PBS buﬀer containing 0.05% (v/v) Tween
20 at 25 °C for 1 h. The unlabeled peptides or positive controls
(nutlin) were diluted twofold serially in PBS buﬀer containing
0.05% (v/v) Tween 20 for a 16-point titration curve (20 μL per
well). To each well containing the unlabeled compound was
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added the TAMRA-labeled tracer/MDM2 solution (20 μL),
and the mixture was incubated for 1 h at 25 °C before the
measurement was taken. Titrations were performed in triplicate.
Data were ﬁtted in GraphPad Prism 5.0 using the equations as
described previously.35
Cellular p53 Reporter Assay. The basic assay was carried
out as previously described in the literature18,36 and is brieﬂy
described as follows. T22 cells stably transfected with a p53-
responsive β-galactosidase reporter,18 kindly provided by Prof.
Sir David Lane, were grown in DMEM with 10% fetal bovine
serum and penicillin/streptomycin. Cells were seeded for 24 h at
8000 cells per 100 μL well in a 96-well black-walled clear ﬂat-
bottom polystyrene plate (Greiner #655090), then treated with
the peptide in triplicate for 18 h at 37 °C in DMEM with 10%
serum and a ﬁnal DMSO concentration of 1%. The β-
galactosidase activity was quantiﬁed using a FluoReporter
LacZ/Galactosidase Quantitation kit (Invitrogen). Fluores-
cence measurements were read on a Tecan Inﬁnite 200 Pro
plate reader. The in situ stapling version of the assay was
identical to the basic assay conditions in all aspects, except that
the cells were treated with a pure unstapled PDI-E peptide (50
μM) and substituted Sondheimer dialkynes (0.5 mM). Control
cells were treated with only substituted Sondheimer dialkynes
(0.5 mM), only unstapled PDI-E peptide (50 μM), or only 1%
DMSO.
Kinetic Analysis. The rate measurement of substituted
Sondheimer dialkynes 1, 11, and 12 in a double strain-promoted
click reaction was performed by monitoring the absorbance of
dialkynes in the presence of an excess amount of benzyl azide.8,15
It has been demonstrated previously with Sondheimer diyne 1
that the ﬁrst cycloaddition leading to the formation of monoyne
intermediate is the rate-determining step of the reaction.8 All
UV measurements were recorded using a Varian Cary 300 UV−
visible spectrophotometer. General procedure: to 1.5 mL 2 mM
solution of substituted dialkyne in MeOH taken in a quartz
cuvette was added 1.5 mL ofMeOH solution of benzyl azide in 3
diﬀerent concentrations (100, 200, and 400 mM; ﬁnal
concentration at 50, 100, and 200 mM, respectively). The
consumption of dialkyne was monitored by UV spectroscopy at
a wavelength that is characteristic for the absorbance of dialkyne
but almost no signiﬁcant absorption is observed for benzyl azide
and products. The experiments were repeated in duplicate for
each concentration of azide. The observed absorbance data at
the characteristic wavelength were plotted versus time and ﬁtted
to a ﬁrst-order exponential decay curve. The pseudo-ﬁrst order
rate constants (k0) were determined by least-squares ﬁtting of
the data to the following exponential equation (y = A × exp(−k0
× x) + y0) using Origin, where A and y0 are constants. The
pseudo-ﬁrst order rate constants determined were plotted versus
the concentration of azide and ﬁtted to a straight line by a linear
regression method usingMicrosoft Oﬃce Excel 16. The slope of
the straight line indicates the second-order rate constant (k) for
the ﬁrst cycloaddition in a double strain-promoted click reaction
of dialkyne with benzyl azide, which is the rate-determining step
of the reaction.
Computational Analysis. All quantum mechanical calcu-
lations were performed with Gaussian 09 Rev D.01. All
geometries were optimized using the B3LYP density functional
and the 6-31G(d) basis set within the conductor-like polarisable
continuum solvation model (CPCM)37,38 for methanol, using
the default integration grid. Vibrational frequencies were
computed for all optimized structures to verify that they were
either minima (zero imaginary frequencies) or transition states
(a single imaginary frequency). Single-point energies E (M06-
2X) were calculated using M06-2X,24 the polarised, triple-ζ
valence quality def2-TZVPP basis set of Weigend and
Ahlrichs,25 and an ultraﬁne integration grid within the CPCM
model (methanol). The strain-promoted click reaction of
substituted Sondheimer dialkynes with methyl azide was
modeled at 298.15 K at 1 atm in methanol. Methyl azide was
employed as it is less conformationally ﬂexible than benzyl azide,
and the calculations showed that it behaves similarly to benzyl
azide in a SPAACwith Sondheimer dialkyne.20 Transition states
were calculated for both anti- and syn-attack of methyl azide on
diynes. Previous computational studies with similar methods
provided results in accordance with the experiment.8,20,29
Computationally obtained structures were illustrated with
PyMOL. The Gibbs free energy values were determined by
addition of the B3LYP thermal correction to the M06-2X
energies.26 This approach has previously been shown to give
reliable results when modeling organic reaction.27,28
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